Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B |
| Cost of Revenue | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B |
| Gross Profit | $36.62B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B | $16.81B | $15.53B |
| Gross Margin | 81.31% | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 77.73% |
| Operating Expenses | $19.12B | $16.25B | $13.26B | $13.07B | $11.85B | $11.60B | $10.79B | $11.28B |
| Operating Income | $17.50B | $10.79B | $8.65B | $7.93B | $7.21B | $6.00B | $6.03B | $4.25B |
| Operating Margin | 38.86% | 31.61% | 30.32% | 28.01% | 29.38% | 26.88% | 28.04% | 21.28% |
| Net Income | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | $-204.10M |
| Net Margin | 23.51% | 15.36% | 21.88% | 19.71% | 25.24% | 37.27% | 15.04% | -1.02% |
| EPS (Basic) | $11.76 | $5.83 | $6.57 | $5.85 | $6.47 | $8.69 | $3.14 | $-0.19 |
| EBITDA | $15.23B | $8.57B | $8.66B | $8.04B | $8.91B | $6.90B | $5.53B | $4.10B |
| Stock Option Compensation Expense | $645.60M | $628.50M | $371.10M | $342.80M | $308.10M | $312.40M | $279.50M | $281.30M |
| Price To Earnings Ratio | 65.65 | 100.04 | 55.66 | 47.19 | 26.08 | 15.13 | 36.80 | -435.34 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $695.27B | $524.27B | $347.61B | $263.42B | $161.51B | $125.85B | $118.93B | $88.85B |